Thrombotic Risk Stratification and Intensive Statin Therapy for Secondary Prevention of Coronary Artery Disease - Insights From the REAL-CAD Study.
暂无分享,去创建一个
M. Matsuzaki | Takeshi Kimura | H. Daida | Y. Ozaki | T. Morimoto | H. Shiomi | R. Nagai | Masahiro Natsuaki | Hirotoshi Watanabe | K. Yamaji | N. Saito | Y. Furukawa | S. Suwa | Y. Nakagawa | Teruo Inoue | K. Miyauchi | Hiroshi Iwata | S. Iimuro | I. Sakuma | Y. Nishihata | Retsu Fujita | Naritatsu Saito | Teruo Inoue
[1] J. Ferrières,et al. Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries. , 2020, Archives of cardiovascular diseases.
[2] P. Stella,et al. Direct comparison of predictive performance of PRECISE-DAPT versus PARIS versus CREDO-Kyoto: a subanalysis of the ReCre8 trial , 2020, Netherlands Heart Journal.
[3] G. Hindricks,et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.
[4] Petr Ošťádal,et al. Corrigendum to: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2017, European heart journal.
[5] R. Giugliano,et al. Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. , 2017, Journal of the American College of Cardiology.
[6] S. Pocock,et al. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. , 2016, Journal of the American College of Cardiology.
[7] J. Spertus,et al. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. , 2016, JAMA.